Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556173 | 0.80 | CYP19A1 (0.41) | HPGD | |
| SCHEMBL13059722 | 0.80 | CYP19A1 (0.41) | HPGD | |
| SCHEMBL7133227 | 0.80 | CYP19A1 (0.41) | HPGD | |
| SCHEMBL1736059 | 0.72 | ALOX15 (0.37) | — | |
| SCHEMBL8713295 | 0.64 | PKM (0.31) | — | |
| SCHEMBL14624782 | 0.64 | TSHR (0.36) | — | |
| SCHEMBL4771757 | 0.62 | EPHX1 (0.33) | — | |
| SCHEMBL1536314 | 0.62 | EPHX1 (0.33) | — | |
| SCHEMBL14524046 | 0.62 | CYP3A4 (0.34) | — | |
| SCHEMBL28376231 | 0.62 | TSHR (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169774-B2 | Cephalotaxane derivatives and their processes of preparation and purification | STRAGEN PHARMA S.A. (CH) | 2007-01-30 | — | — | US | disclosed |
| US-20060234999-A1 | Cephalotaxane derivatives and their processes of preparation and purification | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2006-10-19 | — | — | US | disclosed |
| US-20050090484-A1 | Cephalotaxane derivatives and their processes of preparation and purification | IVAX International GmbH (CH) | 2005-04-28 | — | — | US | disclosed |
| EP-1064285-B1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | STRAGEN PHARMA SA (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-6831180-B1 | Substituted tertiary carboxylic oxacycloalkane acids, used to prepare anhydro-homo-harringtonic acids by semi-synthesis; hydroxyl function of a cephalotaxane is esterified with a 2-carboxyl-2-alkyl-1-oxacycloalkane claimed intermediate; (indexing from 7169774 added) | STRAGEN PHARMA SA. (CH) | 2004-12-14 | — | — | US | disclosed |
| US-6613900-B2 | Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. | ONCOPHARM CORPORATION | 2003-09-02 | — | — | US | disclosed |
| EP-1064285-A1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | Oncopharm Corporation (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999048894-A1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | ONCOPHARM CORPORATION (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234999-A1 | Cephalotaxane derivatives and their processes of preparation and purification | UGT1A7, CYP8B1, UGT2B7 | GLA 3651/4885HPGD 2654/4885 |
| US-20050090484-A1 | Cephalotaxane derivatives and their processes of preparation and purification | UGT1A7, CYP8B1, UGT2B7 | GLA 3651/4885HPGD 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.